“We are developing laws and regulations that help people with lethal diseases to die with dignity. We should do the same to help them live!”

John-Peter Bradford

“I am tired of treating cancer patients with drugs that don’t work.”

― Razelle Kurzrock, M.D.

“Sometimes doing your best is not good enough.  Sometimes you must do what is required.”

― Winston S. Churchill

“… streamlining unnecessarily complex regulation could save thousands of life-years in Canada alone, or millions on a global scale.”

David Stewart, M.D. and John-Peter Bradford

“People who are crazy enough to think that
they can change the world are the ones who do.”

― Steve Jobs

“Never doubt that a small group of thoughtful committed citizens can change the world.  Indeed, it is the only thing that ever has.”

Margaret Mead

“Education is the most powerful weapon you can use to change the world.”

 Nelson Mandela

Life Saving Therapies Network (LSTN)

The Life Saving Therapies Network (LSTN) is an international network of patients, patient groups, oncologists, researchers, regulators, medical ethicists, corporations and others that is focused on solving a major problem in the fight against lethal diseases such as widely metastasized cancer. LSTN is also a call to action… LISTEN… we will be heard.

Developments in precision, gene-targeted medicine, as well as other approaches such as immunotherapy and viral oncolytics are showing great promise for treating lethal diseases. Sometimes referred to collectively as personalized medicine, these targeted therapies also highlight a profound gap in the US and Canada. We don’t have a comprehensive policy or strategy for capitalizing on the promise of personalized medicine. From the perspective of people who have incurable diseases, this lack is deadly. Simply put, it takes too long and costs too much to develop and provide access to effective drug treatments for these diseases.  Current regulatory and research regimes are cumbersome, expensive and fraught with unnecessary delays.

The regulatory system is clogged and strained (for a summary, please click here).

  • The average $800 million it takes to bring a treatment to market means, among other things, that very few drugs actually make it to market. Others that should be tested are not and promising treatments fall by the wayside.
  • Tragically, millions of life-years are lost due to approval delays.  It can take up to 14 years for a drug to be approved; fast-tracked drugs take about six years.
  • Clinical trials are often too complicated and rigid; they must be simpler and easier to access, especially in the case of personalized treatments.
  • Reimbursement for the use of approved drugs takes too long, even in the best jurisdictions.

 

LSTN provides thought leadership and educational resources for creation of progress-centered regulations for precision medicine treatments and diagnostics for lethal diseases like widely metastasized cancers:

  • Clinical research reform to permit faster, less expensive access to new therapies for lethal diseases
  • Reforming regulatory frameworks for the development and approval of precision treatment for lethal diseases
  • Timely and thorough reimbursement for effective lethal disease treatments and companion diagnostics.

We will also contribute generally to crafting an international personalized medicine strategy.

LSTN will

  • Provide a vehicle for communication and cooperative action among the various key stakeholders and opinion leaders via
    • Platforms for debate and discussion
    • Posting key articles and news in the field
    • Providing links among network members
  • Create strategies and a concrete roadmap (action plan) designed to influence research protocols/ regulatory processes and bureaucracies in order to effect faster development of and access to better drugs for lethal diseases in the context of personalized medicine including
    • Creating a strong, single voice – to effect the strategies and plan; a voice that marshals resources from the entire LSTN community: patients, oncologists, the pharma industry, medical ethicists, researchers – maybe even payors and regulators
    • Providing alternative regulatory frameworks and processes and supporting their active consideration
    • Supporting the harmonization of ethics and independent review rules
    • Assisting with clinical trial reform
    • Creative use of social media
    • Supporting publication of books and /or  magazine articles
    • Producing Ted-talk like pieces focused on the issues
  • Participate actively and vigorously in helping to create an international strategy for personalized medicine

LSTN will generate a Roadmap for Change, a three to five year plan which will contain expected outcomes and success measures to create progress-centered regulations that facilitate

  • Clinical research reform to permit faster, less expensive access to new therapies for lethal diseases, and
  • Reforming regulatory frameworks for the development and approval of treatment for lethal diseases.

 

Roundtable

As a key first step, LSTN will bring together key opinion leaders and stakeholders from the Canadian cancer community – oncologists, industry representatives, researchers, patients and caregivers, regulators – to a Roundtable discussion. The purpose of the Roundtable is to frame the Roadmap and generate commitment to it.

  • Preparation for the Roundtable
    • Research and targeted interviews with key players to gather information and opinions
    • A mapping of key stakeholders, their sensitivities and basic interests, perspectives, areas of convergence and divergence
    • Identification of participants in the Roundtable
  • Briefing Document
    • Circulated to participants prior to the Roundtable
    • Thorough, concise understanding of the key issues/challenges, building blocks, roadblocks, and developmental opportunities for moving the conversation forward and affecting regulatory change
    • Basis for a few selected interviews to clarify issues, etc.
  • Roundtable – Process and Outcomes
    • Facilitate discussion in plenary and workshop format
    • Create and clarify overall policy issues and goals
    • Create overview action plan with recommendations for
      • overall milestones
      • metrics by which success will be measured
      • timelines
    • Generate commitment to public discussion of the need for regulatory and research reform in the context of a personalized medicine strategy including suggestions for
      • communication strategy
      • forums for promoting public and specialist discussion of the issues among themselves and with policymakers
      • vehicles for stakeholders can work together to define actionable solutions

 

Making the Roadmap a Reality

The Roadmap for Change will be available to all stakeholders and be continuously updated. It will form a living database of evidence, experiences, recommendations and suggestions — the basis for initiatives by the stakeholders working together, in small groups or separately to achieve our goals.

Featured

The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases

The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases

High costs of complying with drug development regulations slow progress and contribute to high drug prices and, hence, mounting health care costs.  If it is exorbitantly expensive to bring new therapies to approval, fewer agents can be developed with available resources, impeding the emergence of urgently needed treatments and escalating prices by limiting competition.  Excessive regulation produces numerous speed bumps on the road to drug authorization.  Although an explosion of knowledge could fuel rapid advances, progress has been slowed worldwide by inefficient regulatory and clinical research systems that limit access…

To benefit from new cancer drugs, reform the regulatory regime

To benefit from new cancer drugs, reform the regulatory regime

Dr. David J. Stewart is a professor of medicine and head of the Division of…

Redefining cancer: a new paradigm for better and faster treatment innovation

Redefining cancer: a new paradigm for better and faster treatment innovation

Common cancers may arise from several different mutations, and each causative mutation may require different treatment…

The Latest

Is HTA unfairly limiting access to treatments for rare disorders?

Is HTA unfairly limiting access to treatments for rare disorders?

What are the consequences for patients when methods for Health Technology Assessment (HTA) are too rigid? Interesting new research suggests[...]
U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009

U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009

Abstract The U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research is responsible for evaluating drug safety a[...]
Equipoise abandoned? Randomization and clinical trials

Equipoise abandoned? Randomization and clinical trials

Randomized, clinical trials are the strongest method we have to define the efficacy of new drugs. Recently, however, novel agents that show [...]
THE TOP 5 MYTHS ABOUT CLINICAL TRIALS

THE TOP 5 MYTHS ABOUT CLINICAL TRIALS

Dr. Antoinette Wozniak, medical oncologist at Karmanos Cancer Institute and Free to Breathe Board of Directors member, is passionate about furtherin[...]
INSPIRING RESEARCH - WHAT DRIVES A CLINICAL TRIALS RESEARCHER

INSPIRING RESEARCH - WHAT DRIVES A CLINICAL TRIALS RESEARCHER

THROUGH DR. ALEXANDER SPIRA, DIRECTOR OF THE VIRGINIA CANCER SPECIALISTS CLINICAL RESEARCH PROGRAM, WE EXPERIENCE THE CHALLENGES CLINICAL TRIAL RESE[...]
A CLINICAL TRIAL CHANGED MY OUTLOOK

A CLINICAL TRIAL CHANGED MY OUTLOOK

Bill Schrul, a stage 4 lung cancer survivor, shares how a clinical trial has changed his outlook. I’m Bill Schrul, and I was diagnosed with S[...]